Related Experiment Video

Updated: Jun 4, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms

Jayashree Shanker1, Armen Yuri Gasparyan, George D Kitas

  • 1Thrombosis Research Institute, Bommasandra Industrial Area, Anekal Taluk, Bangalore, India. jayashreeshanker@triindia.org.in

Current Vascular Pharmacology
|February 15, 2011
PubMed

Insights

Genetic variations in platelet receptors influence antiplatelet drug effectiveness. Analyzing these genetic polymorphisms may help personalize antiplatelet therapy and prevent cardiovascular events.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Hematology

Background:

  • Platelets are key in thrombosis and cardiovascular diseases.
  • Aspirin and clopidogrel are common antiplatelet drugs, but efficacy varies.
  • This variability, termed 'antiplatelet resistance,' necessitates understanding underlying mechanisms.

Purpose of the Study:

  • To investigate the role of genetic polymorphisms in platelet receptor genes.
  • To explore the association between genetic variants and antiplatelet therapy response.
  • To assess the potential for personalized antiplatelet treatment strategies.

Main Methods:

  • Review of prospective studies on antiplatelet efficacy.
  • Focus on genetic polymorphisms in platelet receptor genes (e.g., P2Y12, GP IIb/IIIa, CYP family).
  • Consideration of genetic haplotypes and platelet function quantification.

Main Results:

  • Specific genetic variants in platelet receptors are linked to variable responses to antiplatelet agents.
  • Genetic polymorphisms and haplotypes can predict antiplatelet drug response.
  • Combined genetic and platelet function testing may offer predictive value.

Conclusions:

  • Genetic profiling of platelet receptors can inform antiplatelet therapy.
  • Personalized antiplatelet treatment and thrombotic event prevention are potential benefits.
  • Further research on cost-effectiveness of genetic and platelet function testing is required.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...